Faculty of Medicine, Department of Nephrology Adana, Cukurova University, Adana, Turkey.
Faculty of Medicine, Department of Pathology Adana, Cukurova University, Adana, Turkey.
Int J Clin Pract. 2021 Apr;75(4):e13855. doi: 10.1111/ijcp.13855. Epub 2020 Dec 13.
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in nondiabetic adults. M-type phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A) are known as target podocyte antigens in membranous nephropathy (MN). Antibodies against these podocyte antigens are used in the initiation of treatment and response monitoring. However, the relationship between renal podocyte antigens and treatment response is not clear yet. We evaluated the relationship between immunohistochemical PLA2R, THSD7A and IgG4 staining, clinical findings and treatment response in kidney biopsies.
Fifty-eight patients with MN were included in this retrospective study. In the renal biopsy samples of the patients, PLA2R, THSD7A and IgG4 were stained immunohistochemically and evaluated by light microscopy. The clinical, laboratory and treatment results of the patients were obtained from the hospital records.
The study included a total of 58 patients with MN and a mean follow-up period of 32.3 ± 19.7 months. In patients with primary MN; PLA2R, THSD7A and IgG4 were positive in 57.1% (n = 28), 12.2% (n = 6) and 69.4% (n = 34), respectively. Only PLA2R staining was distinctly higher in patients with primary MN than secondary MN (P = .025). Dual positivity (PLA2R + THSD7A) was detected in five (10.2%) of patients with primary MN. We did not determine any relationship between the PLA2R, THSD7A and IgG4 staining patterns and treatment response of the patients.
It was found no correlation between PLA2R, THSD7A and IgG4 staining in kidney tissue and treatment response. Interestingly, dual positivity (PLA2R + THSD7A) was detected only in primary MN.
膜性肾病(MN)是成年非糖尿病患者肾病综合征最常见的病因。M 型磷脂酶 A2 受体(PLA2R)、血小板反应蛋白 1 型结构域包含 7A(THSD7A)是膜性肾病(MN)中已知的靶足细胞抗原。针对这些足细胞抗原的抗体用于启动治疗和监测反应。然而,肾足细胞抗原与治疗反应之间的关系尚不清楚。我们评估了肾活检中免疫组化 PLA2R、THSD7A 和 IgG4 染色、临床特征和治疗反应之间的关系。
本回顾性研究纳入 58 例 MN 患者。对患者的肾活检标本进行 PLA2R、THSD7A 和 IgG4 免疫组化染色,并通过光学显微镜进行评估。从病历中获取患者的临床、实验室和治疗结果。
本研究共纳入 58 例 MN 患者,平均随访时间为 32.3±19.7 个月。在原发性 MN 患者中;PLA2R、THSD7A 和 IgG4 阳性率分别为 57.1%(n=28)、12.2%(n=6)和 69.4%(n=34)。原发性 MN 患者中 PLA2R 染色明显高于继发性 MN(P=0.025)。5 例(10.2%)原发性 MN 患者存在双重阳性(PLA2R+THSD7A)。我们未发现患者 PLA2R、THSD7A 和 IgG4 染色模式与治疗反应之间存在任何关系。
未发现肾组织中 PLA2R、THSD7A 和 IgG4 染色与治疗反应之间存在相关性。有趣的是,仅在原发性 MN 中检测到双重阳性(PLA2R+THSD7A)。